|
|
Advantages and risks of using CDK4/6 inhibitors, including palbociclib, in first-line therapy for HR+ metastatic breast cancerТ. 14, №4 (56) Experience of management of breast cancer in pregnant patient of 28–29 weeks of gestationAuthors: Dronova V.L. Dronov O.I. Lyalkin S.A. Mokryk О.М.... Т. 14, №4 (56) Peculiarities of treatment of patients with laryngeal cancerAuthors: Lukach E.V. Serezhko Yu.O. Tsymbalyuk E.M. Т. 14, №4 (56) The impact of tumor burden score on postoperative morbidity and survival in colorectal cancer patients with liver metastasesAuthors: Burlaka A. Bezverhnyi V. Mykytyuk A. Dupyk M.... Т. 14, №4 (56) |
|